BMRN insider trading
NasdaqGS HealthcareBIOMARIN PHARMACEUTICAL INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About BIOMARIN PHARMACEUTICAL INC
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
Company website: www.biomarin.com
BMRN insider activity at a glance
FilingIQ has scored 1,353 insider transactions for BMRN since May 12, 2014. The most recent filing in our index is dated May 7, 2026.
Across the full history, 3 open-market purchases
and 389 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on BMRN insider trades is 58.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest BMRN Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading BMRN
13F funds holding BMRN
Frequently asked
- How many insider trades does FilingIQ track for BMRN?
- FilingIQ tracks 1,353 Form 4 insider transactions for BMRN (BIOMARIN PHARMACEUTICAL INC), covering filings from May 12, 2014 onwards. 35 of those were filed in the last 90 days.
- Are BMRN insiders net buyers or net sellers?
- Across the full Form 4 history for BMRN, 3 transactions (0%) were open-market purchases and 389 (29%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does BMRN insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is BMRN in?
- BIOMARIN PHARMACEUTICAL INC (BMRN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $12.09B.
Methodology & sources
Every BMRN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.